# Cue Biopharma, Inc. (CUE)

**Exchange:** NASDAQ  
**Market cap:** $2.58B  
**Price:** $27.26 (-2.15%)

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $27M | — | -$27M | -$27M | — |
| 2024 | $9M | — | -$42M | -$41M | — |
| 2023 | $5M | — | -$52M | -$51M | — |
| 2022 | $1M | — | -$53M | -$53M | — |
| 2021 | $15M | — | -$44M | -$44M | — |
| 2020 | $3M | — | -$45M | -$45M | — |
| 2019 | $3M | — | -$37M | -$37M | — |
| 2018 | $1M | — | -$39M | -$39M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $42M | $16M | $26M | $27M | — |
| 2024 | $32M | $15M | $17M | $22M | — |
| 2023 | $62M | $24M | $37M | $49M | $4M |
| 2022 | $91M | $26M | $66M | $52M | $8M |
| 2021 | $83M | $18M | $65M | $64M | — |
| 2020 | $100M | $21M | $79M | $75M | — |
| 2019 | $72M | $17M | $55M | $44M | — |
| 2018 | $45M | $11M | $34M | $21M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$22M | $177,000 | -$22M |
| 2024 | -$36M | $66,000 | -$36M |
| 2023 | -$40M | — | -$40M |
| 2022 | -$42M | $171,000 | -$42M |
| 2021 | -$39M | $913,039 | -$40M |
| 2020 | -$32M | $595,259 | -$33M |
| 2019 | -$31M | $46,353 | -$31M |
| 2018 | -$26M | $2M | -$28M |
| 2017 | -$12M | $1M | -$13M |

Source: [CompaniesByCap](https://companiesbycap.com/company/CUE)